Primary Endpoint Analysis from a Response Adaptive Phase II Clinical Trial of Carfilzomib, Lenalidomide, Dexamethasone Plus Daratumumab (KRd-Dara) in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

被引：2

作者：

Bhutani, Manisha ^{[1
]}

Robinson, Myra ^{[2
]}

Atrash, Shebli ^{[1
]}

Paul, Barry ^{[1
]}

Pineda-Roman, Mauricio ^{[1
]}

Foureau, David ^{[3
]}

Varga, Cindy ^{[1
]}

Friend, Reed ^{[1
]}

Begic, Xhevahire ^{[4
]}

Norek, Sarah ^{[4
]}

Drennan, Tiffany ^{[5
]}

Anderson, Michelle B. ^{[6
]}

Symanowski, James ^{[2
]}

Voorhees, Peter M. ^{[7
]}

Usmani, Saad Z. ^{[8
]}

机构：

[1] Atrium Hlth, Dept Hematol Oncol & Blood Disorders, Levine Canc Inst, Charlotte, NC USA

[2] Atrium Hlth, Levine Canc Inst, Dept Canc Biostat, Charlotte, NC USA

[3] Atrium Hlth, Levine Canc Inst, Immune Monitoring Core Lab, Charlotte, NC USA

[4] Atrium Hlth, Levine Canc Inst, Sponsored Res Coordinating Ctr, Charlotte, NC USA

[5] Atrium Hlth, Levine Canc Inst, Clin Trials Unit, Charlotte, NC USA

[6] Atrium Hlth, Levine Canc Inst, Biostat & Data Sci, Charlotte, NC USA

[7] Wake Forest Univ, Sch Med, Atrium Hlth, Dept Hematol Oncol & Blood Disorders,Levine Canc, Charlotte, NC USA

[8] Mem Sloan Kettering Canc Ctr, Dept Med, Div Hematol Oncol, Myeloma Serv, 1275 York Ave, New York, NY 10021 USA

来源：

关键词：

D O I：

10.1182/blood-2023-174972

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4